The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Fruquintinib plus best supportive care for patients with metastatic colorectal cancer: Characterization of patients who had an overall survival of =10 months in the FRESCO-2 study.
 
Stefan Kasper
Honoraria - Amgen; Art Tempi; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; MSD; Onkowissen; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Art Tempi; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; MSD; Novartis; Onkowissen; Seagen; Servier; Takeda
Research Funding - Bristol-Myers Squibb; Lilly; Roche
 
Andrea Sartore-Bianchi
Honoraria - Guardant Health
Consulting or Advisory Role - Bayer; Pierre Fabre; SERVIER; Takeda
 
Violaine Randrian
Honoraria - Takeda
 
Chiara Cremolini
Honoraria - Amgen; Bayer; GlaxoSmithKline; Merck; Merck; MSD; Pierre Fabre; Roche; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Bayer; Bicara Therapeutics; MSD; Nordic Bioscience; Pierre Fabre; Revolution Medicines; Roche; Rottapharm Biotech; Takeda
Speakers' Bureau - Merck; MSD; Pierre Fabre; SERVIER
Research Funding - Bayer; Merck; Roche; SERVIER
 
Dirk Arnold
Employment - Asklepios Kliniken
Honoraria - Amgen; AstraZeneca; Boston Scientific; Bristol-Myers Squibb; Eisai Europe; Gilead Sciences; GlaxoSmithKline; Ipsen; Janssen Oncology; Merck Serono; Merck Sharp and Dome; Pierre Fabre; Sanofi/Regeneron; Seagen; SERVIER; Sirtex Medical; Takeda; TERUMO; Viatris
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck Serono; MSD Oncology
Research Funding - Oncolytics (Inst)
Travel, Accommodations, Expenses - Boston Scientific
(OPTIONAL) Uncompensated Relationships - Deputy Editor Clin Colorectal Cancer; ESMO; ESMO Open
 
Arvind Dasari
Consulting or Advisory Role - HutcMed; Illumina/GRAIL; Personalis; SIRTIS; Takeda
Research Funding - Eisai (Inst); Guardant Health (Inst); Hutchison MediPharma (Inst); Merck (Inst); Natera (Inst); XENCOR (Inst)
Travel, Accommodations, Expenses - Hutchison MediPharma; Takeda
 
Cathy Eng
Consulting or Advisory Role - Abbvie; Amgen (I); California Institute for Regenerative Medicine (CIRM) (I); Hookipa Biotech; IgM Biosciences (I); Merck Serono; Pfizer; Seagen; Taiho Oncology (I); Takeda
Research Funding - Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Takeda
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Helyon; Incyte; Lilly; Merck Serono; MSD; Nimbus Therapeutics; Rottapharm Biotech; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Elena Elez
Honoraria - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; Janssen; Lilly; Medscape; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Sanofi/Aventis; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cure Teq AG; Janssen; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics Inc.; RIN Institute Inc.; Roche; Roche; Sanofi; Seagen; SERVIER; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bioncotech (Inst); Biontech Rna Pharmaceuticals GMBH (Inst); Biontech Small Molecules GMBH (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim Spain (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Inc. (Inst); Debiopharm Group (Inst); Genentech (Inst); Gercor (Inst); HalioDx (Inst); Hoffmann-La-Roche Ltd. (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Nouscom SRL. (Inst); Novartis (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); PledPharma (Inst); Redx Pharma (Inst); Roche (Inst); Sanofi (Inst); Scandion Oncology (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); Taiho Pharma USA (Inst); Taiho Pharmaceutical (Inst); WntResearch (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; Janssen; Lilly; Medscape; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Sanofi; Seagan; SERVIER; Takeda
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; MSD K.K.; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Molecular Health (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Alberto Sobrero
Consulting or Advisory Role - Amgen; Bayer; BMS; GlaxoSmithKline; MSD Oncology; SERVIER
Speakers' Bureau - amgen; AstraZeneca; Bayer; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bayer
 
James Yao
Consulting or Advisory Role - Acrotech Biopharma; Amgen; Crinetics Pharmaceuticals; Exelixis; Hutchison MediPharma; Ipsen
Research Funding - Advanced Accelerator Applications; Novartis
 
Howard Hochster
Stock and Other Ownership Interests - Compass Therapeutics
Consulting or Advisory Role - Processa Pharmaceuticals; Takeda
Expert Testimony - Natera
Travel, Accommodations, Expenses - Takeda
Other Relationship - Seagen
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; GlaxoSmithKline; Hookipa Biotech; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; TERUMO
 
David Tougeron
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; Servier/Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; BMS; MSD; Novartis; Pierre Fabre; Sanofi; SERVIER; Takeda
Research Funding - BTG (Inst); Gilead Sciences (Inst); MSD (Inst); Pierre Fabre (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Roche; SERVIER
 
Ziji Yu
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Cynthia Dong
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
William Schelman
Employment - HUTCHMED
Stock and Other Ownership Interests - HUTCHMED
 
François Ghiringhelli
Honoraria - roche
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Roche/Genentech; Roche/Genentech